Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cytotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14653240902960411PMID 19530029
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients.

  2008cited by this paper
• WT1 peptide vaccine for the treatment of cancer.

  2008cited by this paper
• Effective Clinical-scale Production of Dendritic Cell Vaccines by Monocyte Elutriation Directly in Medium, Subsequent Culture in Bags and Final Antigen Loading Using Peptides or RNA Transfection

  2007cited by this paper
• Immunosuppression induced by immature dendritic cells is mediated by TGF-β/IL-10 double-positive CD4+ regulatory T cells

  2007cited by this paper
• mRNA-based gene transfer as a tool for gene and cell therapy.

  2007cited by this paper
• Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

  2007cited by this paper
• Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors.

  2006cited by this paper
• Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.

  2006cited by this paper
• Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma

  2006cited by this paper
• Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.

  2006cited by this paper
• Phase I/II study of vaccination with dendritic‐like leukaemia cells for the immunotherapy of acute myeloid leukaemia

  2006cited by this paper
• Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity1

  2005cited by this paper
• Generation of an Optimized Polyvalent Monocyte-Derived Dendritic Cell Vaccine by Transfecting Defined RNAs after Rather Than before Maturation1

  2005cited by this paper
• Drug therapy for acute myeloid leukemia.

  2005cited by this paper
• Antigen-specific cellular immunotherapy of leukemia

  2005cited by this paper
• Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells.

  2005cited by this paper
• Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells

  2005cited by this paper
• A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.

  2004cited by this paper
• Development of a technology platform for large-scale clinical grade production of DC.

  2004cited by this paper
• Current issues in delivering DCs for immunotherapy.

  2004cited by this paper
• Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

  2004cited by this paper
• Dendritic cell immunotherapy: mapping the way

  2004cited by this paper
• Activation of Monocytes via the CD14 Receptor Leads to the Enhanced Lentiviral Transduction of Immature Dendritic Cells

  2004cited by this paper
• Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

  2004cited by this paper
• Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma.

  2004cited by this paper
• A non-viral gene delivery system designed for clinical use.

  2003cited by this paper
• Large-Scale Immunomagnetic Selection of CD14+ Monocytes to Generate Dendritic Cells for Cancer Immunotherapy: A Phase I Study

  2003cited by this paper
• Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection.

  2003cited by this paper
• Efficacy of Dendritic Cell Generation for Clinical Use: Recovery and Purity of Monocytes and Mature Dendritic Cells after Immunomagnetic Sorting or Adherence Selection of CD14+ Starting Populations

  2003cited by this paper
• Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

  2003cited by this paper
• A closed and single‐use system for monocyte enrichment: potential for dendritic cell generation for clinical applications

  2003cited by this paper
• CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.

  2002cited by this paper
• Generation of large numbers of dendritic cells in a closed system using Cell Factories.

  2002cited by this paper
• Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories.

  2002cited by this paper
• Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells.

  2001cited by this paper
• Development of Th1-Inducing Capacity in Myeloid Dendritic Cells Requires Environmental Instruction1

  2000cited by this paper
• Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth

  1999cited by this paper
• Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application.

  1999cited by this paper
• Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells.

  1999cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions

  1997cited by this paper
• Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia.

  1997cited by this paper
• Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes.

  1996cited by this paper
• Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.

  1995cited by this paper
• Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.

  1995cited by this paper
• Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients.

  1994cited by this paper
• WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.

  1994cited by this paper
• Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

  1994cited by this paper
• Proliferating dendritic cell progenitors in human blood

  1994cited by this paper
• Dendritic cells: antigen presentation, accessory function and clinical relevance.

  1993cited by this paper
• GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

  1992cited by this paper
• GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells.

  1992cited by this paper
• Expression of the Wilms' tumor gene (WT1) in human leukemias.

  1992cited by this paper

• The Application of mRNA Technology for Vaccine Production—Current State of Knowledge

  2025cites this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cites this paper
• mRNA-based vaccines and therapies - a revolutionary approach for conquering fast-spreading infections and other clinical applications: a review.

  2025cites this paper
• Stimuli-Responsive Nanomaterials for the Precision Delivery of mRNA Cancer Vaccines

  2025cites this paper
• Lipid nanoparticle-assisted mRNA therapy for cancer treatment

  2025cites this paper
• Dendritic Cell Therapy in Immuno-Oncology: A Potentially Key Component of Anti-Cancer Immunotherapies

  2025cites this paper
• Dendritic Cells as a Therapeutic Strategy in Acute Myeloid Leukemia: Vaccines

  2024cites this paper
• The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases

  2024cites this paper
• Cancer mRNA vaccines: clinical advances and future opportunities

  2024cites this paper
• mRNA vaccines: a new era in vaccine development

  2024cites this paper
• Cellular respiration in dendritic cells: Exploring oxygen-dependent pathways for potential therapeutic interventions.

  2024cites this paper
• Messenger RNA vaccines and their delivery strategies: A journey from infectious diseases to cancer.

  2023cites this paper
• Therapeutic cancer vaccines: advancements, challenges and prospects

  2023cites this paper
• mRNA vaccines in disease prevention and treatment

  2023cites this paper
• DC vaccine enhances CAR-T cell antitumor activity by overcoming T cell exhaustion and promoting T cell infiltration in solid tumors

  2023cites this paper
• An mRNA mix redirects dendritic cells towards an antiviral program, inducing anticancer cytotoxic stem cell and central memory CD8+ T cells

  2023cites this paper
• Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development

  2023cites this paper
• Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases

  2022cites this paper
• Capture and reagent exchange (CARE) wells for cell isolation, labeling, and characterization

  2022cites this paper
• Potential of mRNA vaccines to become versatile cancer vaccines

  2022cites this paper
• Clinical and immunological effects of mRNA vaccines in malignant diseases

  2021cites this paper
• Identification of mouse helper epitopes for WT1-specific CD4+ T cells

  2021cites this paper
• The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy

  2021cites this paper
• Wilms' Tumor 1 (WT1): The Vaccine for Cancer.

  2020cites this paper
• Physical transfection technologies for macrophages and dendritic cells in immunotherapy

  2020cites this paper
• Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready ‘N Able to Improve Clinical Outcome?

  2020cites this paper
• A Bird’s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers

  2020cites this paper
• Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates

  2020cites this paper
• Clinical Grade Production of Wilms’ Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation

  2020cites this paper
• Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines.

  2020cites this paper
• Preservation of cell-based immunotherapies for clinical trials.

  2019cites this paper
• Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia

  2019cites this paper
• PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood

  2019influential citation
• Adoptive cell therapy for acute myeloid leukemia

  2019cites this paper
• Dendritic cells as cancer therapeutics.

  2019cites this paper
• An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination.

  2018cites this paper
• Freezing of dendritic cells with trehalose as an additive in the conventional freezing medium results in improved recovery after cryopreservation

  2018cites this paper
• mRNA vaccines — a new era in vaccinology

  2018cites this paper
• Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing

  2018cites this paper
• A new developing class of gene delivery: messenger RNA-based therapeutics.

  2017cites this paper
• Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation.

  2017cites this paper
• Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use

  2017cites this paper
• Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells.

  2017cites this paper
• Targeting of the WT191–138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination

  2017cites this paper
• Hematologic neoplasms: Dendritic cells vaccines in motion.

  2017cites this paper
• Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.

  2017cites this paper
• Understanding dendritic cell immunotherapy in ovarian cancer

  2016cites this paper
• Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.

  2016cites this paper
• Viral and Synthetic RNA Vector Technologies and Applications.

  2016cites this paper
• Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic Cells.

  2016cites this paper
• Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine

  2016cites this paper
• the archived peer-reviewed author-version of: Medical costs of treatment and survival of patients with acute myeloid leukemia in

  2016cites this paper
• Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.

  2016cites this paper
• Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium.

  2016cites this paper
• CMRF-56+ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses

  2016cites this paper
• Dendritic Cell Targets for Self-Replicating RNA Vaccines

  2015cites this paper
• Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation

  2015cites this paper
• DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies

  2015cites this paper
• Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond

  2015cites this paper
• New Advances in Cell-Based Drug and Gene Delivery Systems

  2015cites this paper
• Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions

  2015cites this paper
• Engineering monocyte-derived dendritic cells to secrete interferon- enhances their ability to promote adaptive and innate anti-tumor immune effector functions Reference:

  2015cites this paper
• mRNA transcript therapy

  2015cites this paper
• Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemias

  2015cites this paper
• Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies

  2014cites this paper
• Dendritic cell vaccine against leukemia: advances and perspectives.

  2014cites this paper
• Lentivirus-Induced Dendritic Cells (iDC) for Immune-Regenerative Therapies in Cancer and Stem Cell Transplantation

  2014cites this paper
• Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA–Transfected Dendritic Cells

  2014cites this paper
• New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia

  2014cites this paper
• mRNA-based therapeutics — developing a new class of drugs

  2014cites this paper
• Interleukin-12 p 70 Expression by Dendritic Cells of HIV-1-Infected Patients Fails to Stimulate gag-Specific Immune Responses

  2014cites this paper
• Ex Vivo Gene Therapy

  2014cites this paper
• RNA vaccines for anti-tumor therapy

  2013cites this paper
• The interaction of electric fields with vesicles and cells: A study on electrodeformation and electroporation

  2013cites this paper
• Dendritic Cell-Based Immunotherapy for Myeloid Leukemias

  2013cites this paper
• Current strategies in immunotherapy for acute myeloid leukemia.

  2013cites this paper
• Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo

  2013cites this paper
• mRNA electroporation as a tool for immunomonitoring.

  2013cites this paper
• Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy

  2013cites this paper
• Tumor-Associated Antigens

  2013cites this paper
• Dendritic cell immunotherapy in ovarian cancer

  2013cites this paper
• Cell-based immunotherapy against gliomas: from bench to bedside.

  2013cites this paper
• Optimization of methodology for production of CD25/CD71 allodepleted donor T cells for clinical use.

  2013cites this paper
• Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.

  2013cites this paper
• Cryopreservation of adenovirus-transfected dendritic cells (DCs) for clinical use.

  2012cites this paper
• Mass spectrometric identification of Varicella-Zoster Virus (VZV) proteins recognized by human T cells

  2012cites this paper
• Développement de l'immunothérapie anti-tumorale médiée par vecteur bactérien vivant basé sur le système de sécrétion de type III de Pseudomonas aeruginosa

  2012cites this paper
• Interleukin-12p70 Expression by Dendritic Cells of HIV-1-Infected Patients Fails to Stimulate gag-Specific Immune Responses

  2012cites this paper
• Dendritic cell vaccination in acute myeloid leukemia.

  2012cites this paper
• Dendritic Cells The Tumor Microenvironment and the Challenges for an Effective Antitumor Vaccination

  2012cites this paper
• Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

  2012cites this paper
• Trial watch

  2012cites this paper
• Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen.

  2012cites this paper
• Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation

  2012cites this paper
• Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia

  2011cites this paper
• Modeling of electroporation mediated molecular delivery

  2011cites this paper
• Vaccines as consolidation therapy for myeloid leukemia

  2011cites this paper
• Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia

  2011cites this paper
• In vitro and in vivo mRNA delivery using lipid-enveloped pHresponsive polymer nanoparticles

  2011cites this paper
• Engineering dendritic cells to enhance cancer immunotherapy.

  2011cites this paper